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BACKGROUND: The strength of association and optimal levels for risk 
factors related to excess risk of death and cardiovascular outcomes in type 
1 diabetes mellitus have been sparsely studied.
METHODS: In a national observational cohort study from the Swedish 
National Diabetes Register from 1998 to 2014, we assessed relative 
prognostic importance of 17 risk factors for death and cardiovascular 
outcomes in individuals with type 1 diabetes mellitus. We used Cox 
regression and machine learning analyses. In addition, we examined 
optimal cut point levels for glycohemoglobin, systolic blood pressure, and 
low-density lipoprotein cholesterol. Patients with type 1 diabetes mellitus 
were followed up until death or study end on December 31, 2013. The 
primary outcomes were death resulting from all causes, fatal/nonfatal 
acute myocardial infarction, fatal/nonfatal stroke, and hospitalization for 
heart failure.
RESULTS: Of 32 611 patients with type 1 diabetes mellitus, 1809 
(5.5%) died during follow-up over 10.4 years. The strongest predictors 
for death and cardiovascular outcomes were glycohemoglobin, 
albuminuria, duration of diabetes mellitus, systolic blood pressure, and 
low-density lipoprotein cholesterol. Glycohemoglobin displayed ≈2% 
higher risk for each 1-mmol/mol increase (equating to ≈22% per 1%  
glycohemoglobin difference), whereas low-density lipoprotein cholesterol 
was associated with 35% to 50% greater risk for each 1-mmol/L increase. 
Microalbuminuria or macroalbuminuria was associated with 2 to 4 times 
greater risk for cardiovascular complications and death. Glycohemoglobin 
<53 mmol/mol (7.0%), systolic blood pressure <140 mm Hg, and 
low-density lipoprotein cholesterol <2.5 mmol/L were associated with 
significantly lower risk for outcomes observed.
CONCLUSIONS: Glycohemoglobin, albuminuria, duration of diabetes 
mellitus, systolic blood pressure, and low-density lipoprotein cholesterol 
appear to be the most important predictors for mortality and 
cardiovascular outcomes in patients with type 1 diabetes mellitus. Lower 
levels for glycohemoglobin, systolic blood pressure, and low-density 
lipoprotein cholesterol than contemporary guideline target levels appear 
to be associated with significantly lower risk for outcomes.
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According to epidemiological studies, individu-als with type 1 diabetes mellitus (T1DM) have markedly increased risk for death and cardio-
vascular outcomes,1 whereas dysglycemia is also associ-
ated with an increased risk of having additional cardio-
vascular risk factors in the short or longer term, as well 
as associated microvascular complications.
The relationship between cardiovascular risk fac-
tors and T1DM warrants further investigation, con-
sidering the known increased risk for death and car-
diovascular complications and the estimated average 
of ≈12 life-years lost for patients with T1DM from 
20 years of age.2 Although some management ap-
proaches for reducing cardiovascular risk have been 
extrapolated from randomized trials in type 2 diabe-
tes mellitus, there remains uncertainty beyond op-
timal glycemia management on how aggressively 
low-density lipoprotein cholesterol (LDL-C) and blood 
pressure should be managed. There is therefore in-
terest in improving our understanding of the adverse 
effects of dysglycemia, the prognostic role of albu-
minuria, and the role of blood pressure and hyper-
cholesterolemia in patients with T1DM at increased 
risk for cardiovascular disease. Our research group 
has previously demonstrated that multiple risk factor 
control is associated with significantly lower risk for 
myocardial infarction (MI) and stroke but has little 
association with risk for heart failure (HF) in individu-
als with T1DM.3 Furthermore, research shows that 
hyperglycemia, the hallmark of T1DM, even below 
recommended guideline levels of 6.9% (or 52 mmol/
mol) is still associated with at least 2-fold excess risk 
of death and cardiovascular disease compared with 
risk in matched control subjects.4
In the present study, we applied both convention-
al and novel statistical approaches to investigate the 
strength of association of 17 cardiovascular risk factors 
to illustrate their predictive ability for death and cardio-
vascular outcomes in individuals with T1DM. In addi-
tion, we analyzed the association between varying lev-
els of selected risk factors—glycohemoglobin (HbA1c), 
systolic blood pressure (SBP), and LDL-C—to determine 
optimal risk factor levels with regard to associations 
with death and cardiovascular outcomes.
METHODS
The data and analytical methods used for this study will not 
be made available to other researchers for purposes of repro-
ducing the results or replicating the procedures. The reason 
for lack of availability is that, by Swedish law that governs 
national health registries, data sets containing sensitive 
patient data cannot be shared publicly. Nevertheless, research 
groups and other health agencies have the option to request 
data from each government agency, including the National 
Diabetes Registry.
Study Design and Support
The Swedish Association of Local Authorities and Regions 
and other nonprofit agencies supported this study. 
Commercial sponsorship was not received. The Regional 
Ethics and Review board of the University of Gothenburg, 
Sweden, approved the study. All study participants provided 
written informed consent.
Data Sources and Study Cohort
The Swedish National Diabetes Register includes information 
on risk factors, medications, and complications in patients 
with both T1DM and type 2 diabetes mellitus, presently with 
>95% of all Swedish citizens with T1DM registered. T1DM is 
Clinical Perspective
What Is New?
• The relative importance of and optimal levels esti-
mated for cardiovascular risk factors for cardiovas-
cular disease and mortality in patients with type 1 
diabetes mellitus are sparsely studied.
• We included 32 611 patients with type 1 diabetes 
mellitus; mean follow-up time was 10.4 years, and 
mean duration of diabetes mellitus was 17.9 years.
• The most important predictors for outcomes were 
glycohemoglobin, albuminuria, duration of diabe-
tes mellitus, systolic blood pressure, and low-density 
lipoprotein cholesterol. Lower levels for glycohe-
moglobin, systolic blood pressure, and low-density 
lipoprotein cholesterol than contemporary target 
levels were associated with lower risk for outcomes.
• Albuminuria was associated with 2 to 4 times 
greater risk for cardiovascular disease and death. 
Each 1-mmol increase in low-density lipoprotein 
cholesterol was associated with 35% to 50% 
higher risk for outcomes.
What Are the Clinical Implications?
• The strongest predictors for mortality and cardiovas-
cular disease in patients with type 1 diabetes mellitus, 
with the exception of age, were mostly conventional 
and modifiable cardiometabolic risk factors.
• This suggests that increased clinical focus for these 
risk factors, particularly in primary prevention, 
should result in the largest relative risk reduction 
for mortality and cardiovascular disease.
• Glycated hemoglobin and albuminuria were the 2 
most important predictors for mortality and cardio-
vascular disease in patients with type 1 diabetes 
mellitus.
• Having lower levels for glycohemoglobin, systolic 
blood pressure, and low-density lipoprotein choles-
terol than recommended in guidelines was asso-
ciated with a lower risk for myocardial infarction, 
stroke, and heart failure.
• Future clinical trials could be designed to test our 
findings.
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defined in the National Diabetes Register on the basis of epi-
demiological criteria: treatment with insulin and a diagnosis 
at ≤30 years of age, a definition that has been validated as 
accurate in >97% of cases.5 Individuals with T1DM and at 
least 1 registration between January 1, 1998, and December 
31, 2012, were included in the study. Information on demo-
graphics and clinical characteristics was captured at baseline, 
that is, the first registration in the registry. Individuals with 
T1DM who met any of the following criteria were excluded: 
body mass index <18.5 kg/m2, history of coronary heart 
disease, MI, stroke, HF, atrial fibrillation, severe chronic kid-
ney disease (estimated glomerular filtration rate [eGFR] ≤29 
mL·min−1·1.73 m−2), and amputation.
Outcomes
Outcomes assessed were death resulting from any cause, fatal/
nonfatal MI, fatal/nonfatal stroke (henceforth referred to as 
stroke), and hospitalization for HF. Outcomes were retrieved 
from hospital discharge records with the use of diagnostic 
codes in the International Classification of Diseases, Ninth 
Revision and Tenth Revision). The specific codes are listed in 
Table I in the online-only Data Supplement. The sensitivity 
and specificity for these outcomes have been validated previ-
ously.6 Patients were followed up from the index date (first 
observation in the National Diabetes Register) until death or 
until December 31, 2013, for all nonfatal outcomes, and until 
December 31, 2014, for death.
Statistical Analysis
We applied different statistical approaches, including Cox 
proportional hazards modeling, analyzing continuous covari-
ates as both continuous and categorical main effects, with 
machine learning analyses to assess the strength of association 
for cardiovascular risk factors. We then compared the relative 
contribution of each predictor in all the models and sorted 
them according to their relative importance in the models for 
death and each of the cardiovascular outcomes. All models 
were adjusted for similar predictors, with the exception of the 
Cox models, which were stratified by sex to account for dif-
ferent underlying hazards for men and women, with age used 
as the time scale.
Using 2 developed applications for the interpretation of 
the Cox proportional hazards model, we determined the rel-
ative importance of 17 cardiovascular risk factors in relation 
to the outcomes of interest. The first statistical approach is 
called estimated explained relative risk, denoted as R2, which 
measures the uncertainty of the conditional event-free sur-
vival time distribution conditional on a set of covariables.7 
In this method, risk factors are modeled as continuous and 
categorical covariates as appropriate. As a complementary 
analysis to the estimated explained relative risk method, 
the strength of associations was estimated with a second 
statistical approach developed for Cox proportional hazard 
models based on the explainable log-likelihood (χ2) attrib-
utable to each predictor in ANOVA, with categorization of 
the continuous covariates for this method (Figure 1A–1D). 
These 2 methods are henceforth referred to as the R2 model 
and the χ2 method.
We also constructed 2 machine learning models (ran-
dom survival forest and gradient boosting; Figure  2A–2D). 
These are both nonparametric ensemble methods that use 
decision trees, which use bagging and boosting techniques 
to increase accuracy, to improve robustness, and to reduce 
variance of predictions.6–8 Analysis of right-censored survival 
data has been implemented into random forest and gradient-
boosting algorithms.8,9 In addition, we measured the relative 
contribution of each predictor in every statistical model and 
analyzed the average percentage for each predictor from all 
4 models for death and cardiovascular outcomes (Figure 3). 
Complementary machine learning models were constructed 
in which age and duration of diabetes mellitus were omitted 
from the models to observe the predictors that experienced 
the greatest relative change in variable importance in the 
absence of these 2 strong interacting and nonmodifiable pre-
dictors. Unstandardized regression coefficients derived from 
Cox models are presented in Figure 3, next to the predictors 
in the dot chart.
We used the Cox model with restricted cubic splines and 4 
knots for each continuous predictor to delineate the associa-
tions between various levels of HbA1c, SBP, and LDL-C and risk 
for cardiovascular events and mortality (Figure 4A–4D). The 
evidence-based, guideline-recommended target level was set 
as reference for each of the 3 risk factors.
Missing data were imputed with the Multivariate 
Imputation by Chained Equations (MICE) methods. 
Calculations were performed in R (version 3.2.3) with the 
following packages: survival, rms, caret, party, gbm, plotmo, 
XGBoost, randomForestSRC, ggRandomForest, and mice 
(Stef van Buuren, Karin Groothuis-Oudshoorn, Alexander 
Robitzsch, Gerko Vink, Lisa Doove, Shahab Jolani; MICE; R 
package version 2.25; 2015). Lists of the variables used in 
the imputation model are presented in Table II in the online-
only Data Supplement. Figures I and II in the online-only 
Data Supplement show the frequency of missing data ele-
ments and the distribution of each parameter before and 
after the imputation.
RESULTS
Study Population
A total of 36 869 individuals with T1DM were iden-
tified. After application of the exclusion criteria, the 
final cohort comprised 32 611 patients (Figure III in 
the online-only Data Supplement). The Table presents 
baseline characteristics for all patients with T1DM, for 
those patients with complete data for all risk factors 
(n=9465), and for patients who had at least 1 missing 
risk factor (n=23 868). Baseline characteristics for pa-
tients according to different age groups, HbA1c , blood 
pressure, and LDL-C levels are presented in Tables III 
and IV in the online-only Data Supplement. Mean age 
at entry in the imputed data set was 33.1 years, and 
46% were women. According to the Table, >60% 
of the entire cohort has HbA1c levels <70 mmol/mol 
(<8.5%). Median follow-up time was 10.4 years, and 
mean duration of diabetes mellitus was 17.9±13.2 
years. A total of 1809 patients (5.5%) with T1DM died 
during the study period.
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Strength of Association for 
Cardiovascular Outcomes and Mortality
The strengths of association of various risk factors 
for death and cardiovascular outcomes are present-
ed in Figures  1 and 2A through 2D, showing that 
age was the strongest predictor for death and each 
of the cardiovascular outcomes. All risk factors that 
capture some element of time (eg, age, age at onset 
of diabetes mellitus, or duration of diabetes mellitus) 
demonstrated high relative importance measures. 
Figures 1 and 2A show that beyond age, HbA1c and 
albuminuria were the strongest predictors for mortal-
ity. The Cox model results show that HbA1c was by far 
the most important predictor for death, whereas the 
machine learning models indicate a complex interac-
tion among age, SBP, HbA1c, and albuminuria such 
that these predictors experience significant relative 
change in variable importance in the context of each 
of the others. Each 1-mol increase in HbA1c was as-
sociated with 2% higher risk for death (hazard ratio 
[HR], 1.02 [95% CI, 1.017–1.023]; Figure 3), equat-
ing to 22% (19%–26%) risk difference for each 10-
mmol/mol increase. Income and SBP were also strong 
predictors for mortality, with high income associated 
with 51% lower risk (HR, 0.49 [95% CI, 0.42–0.59]) 
and SBP associated with 0.8% higher risk (HR, 1.008 
[95% CI, 1.005–1.012]) per each 1-mm Hg increase, 
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Figure 1. Strength of association for risk factors according to the estimated explained relative risk model (R2) and explained log-likelihood for each 
predictor (χ2) among individuals with type 1 diabetes mellitus. 
These analyses are based on the same Cox hazards model; we stratified for sex and used age as the time scale. An elevated R2 value or overall χ2 suggests that 
the risk factor has a strong relative importance. The estimated explained relative risk model includes covariables that are modeled as continuous and categorical 
variables, whereas the χ2 model includes only categories for each predictor. (A) All-cause mortality, (B) nonfatal/fatal acute myocardial infarction, (C) nonfatal/fatal 
stroke, and (D) hospitalization for heart failure. eGFR indicates estimated glomerular filtration rate; and LDL, low-density lipoprotein.
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equating to 8.3% (5.6%–11.2%) increase per each 
10-mm Hg increase.
Figures  1 and 2B show that duration of diabetes 
mellitus, LDL-C, and HbA1c were the most important 
predictors for MI. The machine learning models suggest 
that duration of diabetes mellitus, albuminuria, and SBP 
have statistically significant interactions with HbA1c. 
Each 1-mmol/L higher LDL-C (38.7 mg/dL) was associ-
ated with higher relative risk for MI (HR, 1.47 [95% 
CI, 1.39–1.55]; Figure  3). The results for stroke were 
similar to those for MI, except for SBP and physical in-
activity, which proved to be more important predictors 
for stroke (Figures 1 and 2C). SBP demonstrated a large 
relative importance compared with other predictors, 
and the Cox model results showed that each 1-mm Hg 
increase in SBP was associated with a 1.5% higher rela-
tive risk (HR, 1.015 [95% CI, 1.011–1.02]) for stroke, 
equating to a 16% (12%–20%) risk difference for each 
10-mm Hg rise.
Figures 1 and 2D suggest that eGFR, HbA
1c, LDL-C, 
SBP, and duration of diabetes mellitus were the most 
important predictors of hospitalization for HF. Com-
parison between the Cox model results and machine 
learning analyses demonstrates that age and duration 
of diabetes mellitus seem to partially account for the 
association of albuminuria, SBP, and HbA1c with HF 
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Figure 2. Strength of association for risk factors according to the random survival forest (mean decrease-accuracy) and gradient-boosting model 
(relative influence). 
We constructed a random survival forest and gradient-boosting model to estimate the relative importance for risk factors and outcomes. The machine learning 
analyses include higher-order interactions between multiple predictors, in contrast to the Cox models. The measure of strength of association for predictors in 
random forest is denoted as mean decrease of accuracy (MDA) and in gradient boosting as relative influence. Risk factors that display a clear and high MDA or 
relative influence compared with other adjacent predictors should be considered relevant. (A) All-cause mortality, (B) nonfatal/fatal acute myocardial infarction, (C) 
nonfatal/fatal stroke, and (D) hospitalization for heart failure. eGFR indicates estimated glomerular filtration rate; and LDL, low-density lipoprotein.
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risk. Albuminuria and eGFR (renal function) remained 
important predictors in the machine learning models, 
whereas the relative importance of HbA1c was reduced. 
The HR for albuminuria was 3.63 (95% CI, 3.05–4.31).
An illustrative example for Figure 3 follows. From the 
R2 model for mortality, we obtain the R2 value for HbA1c 
(0.043 R2), divided by the sum of R2 for all predictors 
(0.126 R2 value), which translates to 34% relative con-
tribution in the R2 model. The relative contribution of 
each predictor is also obtained for the χ2, random forest, 
and gradient-boosting models in a similar fashion. We 
thereafter calculate the average percentage of the rela-
tive contribution from all models and for each outcome. 
These results are presented in Figure 3 and Table V in the 
online-only Data Supplement. The relative importance of 
risk factors, when age and duration of diabetes mellitus 
were omitted from the machine learning models, is pre-
sented in Figure IV in the online-only Data Supplement.
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Figure 3. Strength of association for the most important risk factors derived from the Cox models and machine-learning analyses for all-cause mor-
tality, acute myocardial infarction, stroke, and hospitalization for heart failure. 
The strength of association for predictors was ranked according to highest relative contribution of each risk factor in every model and outcome. In addition to 
the relative importance of risk factors, we estimated the unstandardized regression coefficient with the Cox model. Standardized coefficients would enable direct 
comparison between relative importance of predictors, but this was not possible because albuminuria is a categorical variable. BP indicates blood pressure; eGFR 
estimated glomerular filtration rate; HbA1c, glycohemoglobin; and LDL, low-density lipoprotein.
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Optimal Levels of Cardiovascular Risk 
Factors in Patients With T1DM
Figure 4A through 4D shows the optimal levels for 3 
conventional risk factors—HbA1c, SBP, and LDL-C—for 
each of the key outcomes of interest. Figure 4A shows 
that the lowest risk of mortality was found at levels of 
LDL-C and SBP below those recommended by current 
guidelines, with HbA1c displaying an U-shaped rela-
tionship. As for MI, we observed a clear linear associa-
tion with similar risk trajectories for HbA1c and LDL-C, 
whereas SBP displayed a sigmoidal association. Levels 
below those recommended by guidelines were associ-
ated with the lowest risk for MI for all 3 risk factors 
(Figure 4B). Stroke and MI showed similar associations 
(Figure 4C), except for LDL-C; lipid levels <2.5 mmol/L 
were associated with reduced risk, and elevated lev-
els of LDL-C were not associated with higher risk. For 
hospitalization for HF (Figure 4D), we observed similar 
risk trajectories for all 3 risk factors; that is, levels lower 
than guideline-recommended levels were associated 
with reduced risk.
Interactions Between Age, Duration of 
T1DM, and Cardiovascular Risk Factors
After exhaustive subset research with Cox regression 
and machine learning models, we observed that age, 
duration of diabetes mellitus, SBP, HbA1c, LDL-C, and 
albuminuria/eGFR were interacting with each other on 
different outcomes.
The machine learning models (ie, random survival 
forest and gradient boosting) have an inherent func-
tion to assess complex interaction effects between all 
predictors. Thus, omitting various risk factors from the 
machine learning models allowed us to assess how vari-
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Figure 4. Association between glycohemoglobin (HbA1c), systolic blood pressure (SBP), and low-density lipoprotein (LDL) cholesterol (LDL-C) and 
all-cause mortality, acute myocardial infarction (AMI), stroke, and hospitalization for heart failure. 
Applying a prediction function to the Cox model allows assessment of the relationship between HbA1c, SBP, and LDL-C and risk of mortality, AMI, stroke, and heart 
failure. Continuous variables were modeled with restricted cubic splines, whereas categorical variables were stratified. (A) All-cause mortality, (B) nonfatal/fatal 
AMI, (C) nonfatal/fatal stroke, and (D) hospitalization for heart failure.
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Table. Baseline Characteristics for Patients With T1DM According to HbA1c Levels
 
Patients With T1DM
Patients 
With T1DM 
With at 
Least 1 
Missing 
Risk Factor
Patients 
With 
T1DM 
and No 
Missing 
Data* Overall
HbA1c <48 
mmol/mol
HbA1c  
≥48–<58 
mmol/mol
HbA1c  
≥58–<69 
mmol/mol
HbA1c  
≥69–<80 
mmol/mol
HbA1c  
≥80–<91 
mmol/mol
HbA1c  
≥91 mmol/
mol
Participants, n 23 868 9465 32 611 3462 7736 9451 7016 2871 2075
Women, n (%) 10 942 (45.8) 4345 (45.9) 14 922 (45.8) 1569 (45.3) 3458 (44.7) 4288 (45.4) 3204 (45.7) 1351 (47.1) 1052 (50.7)
Age, mean (SD), y† 34.0 (13.1) 32.3 (13.7) 33.07 (12.94) 30.66 (11.38) 33.43 (13.15) 34.38 (13.45) 33.81 (13.05) 31.91 (12.31) 28.82 (11.06)
Marital status, n (%)
  Divorced 1708 (7.2) 575 (6.1) 2176 (6.7) 151 (4.4) 439 (5.7) 667 (7.1) 559 (8.0) 215 (7.5) 145 (7.0)
  Married 7009 (29.6) 2204 (23.5) 8800 (27.2) 835 (24.2) 2242 (29.2) 2840 (30.3) 1930 (27.7) 626 (22.0) 327 (15.8)
  Single 14 946 (63.2) 6618 (70.4) 21 396 (66.1) 2461 (71.4) 5001 (65.1) 5856 (62.5) 4476 (64.3) 2009 (70.5) 1593 (77.1)
Education, n (%)
  10–12 y 5184 (22.0) 1799 (19.3) 17 544 (54.5) 1745 (51.0) 3943 (51.7) 5072 (54.3) 3980 (57.5) 1630 (57.7) 1174 (57.3)
  ≤9 y 12 756 (54.2) 5133 (55.0) 6737 (20.9) 504 (14.7) 1335 (17.5) 1900 (20.3) 1574 (22.7) 782 (27.7) 642 (31.3)
  College/university 5614 (23.8) 2404 (25.7) 7895 (24.5) 1171 (34.2) 2343 (30.7) 2365 (25.3) 1369 (19.8) 415 (14.7) 232 (11.3)
Income quintile, n (%)
  1 (Lowest) 4868 (20.4) 1666 (17.6) 6404 (19.6) 690 (19.9) 1444 (18.7) 1808 (19.1) 1307 (18.6) 608 (21.2) 547 (26.4)
  2 5491 (23.0) 1897 (20.0) 7204 (22.1) 739 (21.3) 1607 (20.8) 1952 (20.7) 1653 (23.6) 716 (24.9) 537 (25.9)
  3 5350 (22.4) 2139 (22.6) 7311 (22.4) 792 (22.9) 1751 (22.6) 2085 (22.1) 1575 (22.4) 645 (22.5) 463 (22.3)
  4 4562 (19.1) 1966 (20.8) 6398 (19.6) 658 (19.0) 1482 (19.2) 1922 (20.3) 1426 (20.3) 549 (19.1) 361 (17.4)
  5 3596 (15.1) 1797 (19.0) 5294 (16.2) 583 (16.8) 1452 (18.8) 1684 (17.8) 1055 (15.0) 353 (12.3) 167 (8.0)
Immigrant, n (%) 1578 (6.6) 754 (8.0) 2271 (7.0) 285 (8.2) 526 (6.8) 615 (6.5) 457 (6.5) 216 (7.5) 172 (8.3)
Treatment, n (%)
  Blood pressure 
medication (%)
 1754 (18.5) 5439 (16.7) 323 (9.3) 1168 (15.1) 1669 (17.7) 1367 (19.5) 576 (20.1) 336 (16.2)
  Active lipid 
medication (%)
 1288 (14.0) 2609 (8.0) 177 (5.1) 536 (6.9) 820 (8.7) 657 (9.4) 266 (9.3) 153 (7.4)
Information in the National Diabetes Register
  Duration of T1DM, 
mean (SD), y
18.7 (13.4) 17.3 (13.8) 17.89 (13.19) 11.77 (13.24) 17.89 (13.72) 19.75 (13.12) 19.45 (12.65) 17.65 (11.79) 14.62 (11.15)
  Age at onset, 
mean (SD), y
15.3 (7. 7) 15.0 (7.7) 15.18 (7.67) 18.90 (7.17) 15.54 (7.55) 14.63 (7.52) 14.35 (7.63) 14.25 (7.70) 14.20 (7.78)
  HbA1c, mean (SD), 
mmol/mol‡
66.3 (15.9) 64.8 (15.8) 65.84 (15.94) 41.71 (4.59) 53.67 (3.07) 64.13 (3.21) 74.43 (3.09) 85.30 (3.31) 103.28 
(10.75)
  LDL-C, mean (SD), 
mmol/L
2.7 (0.8) 2.6 (0.8) 2.70 (0.85) 2.49 (0.77) 2.59 (0.79) 2.69 (0.83) 2.79 (0.89) 2.85 (0.89) 2.96 (0.95)
  Total cholesterol, 
mean (SD), 
mmol/L
4.8 (1.1) 4.7 (0.9) 4.77 (1.01) 4.47 (0.91) 4.62 (0.93) 4.76 (0.97) 4.90 (1.06) 4.98 (1.05) 5.15 (1.14)
  Smoking, n (%) 2968 (14.0) 1256 (13.3) 4552 (14.0) 299 (8.6) 743 (9.6) 1230 (13.0) 1107 (15.8) 623 (21.7) 550 (26.5)
  Body mass index, 
mean (SD), kg/m2
25.1 (3.9) 25.2 (4.2) 25.09 (3.96) 24.66 (4.07) 24.92 (3.79) 25.14 (3.75) 25.41 (4.06) 25.29 (4.12) 24.87 (4.56)
  SBP, mean (SD), 
mm Hg (SD)
126.3 (16.4) 124.0 (15.4) 125.06 (15.97) 121.82 (14.15) 124.40 (15.27) 125.73 (15.99) 126.41 (16.54) 126.01 (17.16) 123.94 (16.65)
  Diastolic blood 
pressure, mean 
(SD), mm Hg
73.7 (9.05) 72.7 (9.1) 73.36 (9.06) 71.62 (8.75) 72.61 (8.91) 73.35 (8.82) 74.10 (9.27) 74.65 (9.18) 74.87 (9.54)
  eGFR, mean (SD), 
mL·min−1·1.73 
m−2§
100.7 (26.3) 97.7 (25.2) 92.99 (26.76) 93.72 (24.31) 90.93 (25.75) 91.17 (26.37) 92.54 (27.00) 97.06 (28.46) 103.64 (29.60)
(Continued )
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able importance changed, depending on the risk factor 
that was excluded from the model and not allowed to 
interact with other predictors.
The Cox regression and machine learning models 
showed that age was the strongest risk factor for mor-
tality and cardiovascular disease. Including age in the 
Cox models appeared to drown out the effect of the 
remaining variables. This was partially the reason for 
modeling age as the time scale in the Cox models. This 
is not possible in the machine learning models; there-
fore, we were able to observe the effect of age and 
any interaction effects of age on other predictors. Our 
machine learning models revealed that age, duration of 
diabetes mellitus, HbA1c, LDL-C, and albuminuria/eGFR 
were best predicted by each other (Figure 5 provides 
more information).
After comprehensive model construction with ma-
chine learning and Cox models, we observed an inter-
action effect between the abovementioned variables. 
Therefore, we constructed 2-way partial dependence 
plots based on the gradient boosting models to visual-
ize the interacting effect between these variables (Fig-
ure 6 provides more information). In conclusion, these 
analyses indicate that age, duration of diabetes mel-
litus, SBP, HbA1c, LDL-C, and albuminuria/eGFR are the 
most important predictors for mortality and cardiovas-
cular outcomes. In addition, each of these risk factors 
appeared to be a strong predictor of each other and 
seem to interact.
Sensitivity Analyses
 We performed sensitivity analyses to assess the reli-
ability of our models that were based on the imputed 
data set. Therefore, we constructed 2 cohorts of pa-
tients with T1DM. The first cohort included patients 
with no missing data for HbA1c, SBP, LDL-C, albumin-
uria, and smoking (ie, complete cases, n=9465 pa-
tients). The other cohort included patients with at least 
1 missing factor (n=23 868 patients). We constructed a 
Cox regression model using explainable log-likelihood 
explained by each predictor, along with the machine 
learning method called the gradient-boosting model, 
for both cohorts to assess mortality and cardiovascular 
outcomes in patients with T1DM. We did not perform 
these analyses with the random survival forest model or 
the explained relative risk model from the Cox model 
because of excessive processing time from these statis-
tical programs.
The strength of association for patients with T1DM 
and complete cases or at least 1 missing risk factor is 
included in the online-only Data Supplement (for more 
information see Figures V–VIII online-only Data Supple-
ment). The sensitivity analyses demonstrated results 
comparable to our findings from the imputed data set.
DISCUSSION
In this report of 32 611 patients with T1DM derived 
from a population-based nationwide cohort, beyond 
age, the strongest predictors of cardiovascular out-
comes and death were HbA1c, renal function, duration 
of diabetes mellitus, LDL-C, and SBP. Results also sug-
gest that cardiovascular disease and death represent, 
as anticipated, somewhat different pathophysiological 
processes by the variability in the strength of associa-
tions of risk factors analyzed in this cohort of relatively 
young individuals with T1DM. Age was the strongest 
prognostic factor for all outcomes in both the Cox 
model and machine learning analyses. With a focus on 
modifiable factors, HbA1c and albuminuria were robust 
predictors for mortality and hospitalization for HF, in 
contrast to atherothrombotic disease (ie, MI or stroke), 
for which conventional cardiometabolic factors such as 
HbA1c, LDL-C, and SBP demonstrated the greatest rela-
tive prognostic importance. High income was also as-
Albuminuria, n (%)
  No albuminuria 14 336 (84.3) 8127 (85.9) 28 016 (85.9) 3252 (93.9) 6949 (89.8) 8081 (85.5) 5790 (82.5) 2306 (80.3) 1638 (78.9)
  Microalbuminuria 1440 (8.5) 926 (9.8) 2791 (8.6) 136 (3.9) 483 (6.2) 880 (9.3) 740 (10.5) 323 (11.3) 229 (11.0)
  Macroalbuminuria 1225 (7.2) 412 (4.4) 1804 (5.5) 74 (2.1) 304 (3.9) 490 (5.2) 486 (6.9) 242 (8.4) 208 (10.0)
eGFR indicates estimated glomerular filtration rate; HbA1c, glycohemoglobin; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and T1DM, 
type 1 diabetes mellitus.
*Patients with T1DM and no missing risk factors were a subset of patients with complete data for HbA1c, SBP, LDL-C, albuminuria, and smoking.
†Plus-minus values are mean±SD.
‡Concentrations of HbA1c were based on values from the International Federation of Clinical Chemistry and Laboratory Medicine.
§The eGFR was estimated with the use of the Modification of Diet in Renal Disease equation.
Table. Continued
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sociated with a significantly lower risk throughout for 
each of the outcomes.
Our analyses of optimal levels for HbA1c, SBP, and 
LDL-C show that some of these risk factors display al-
most a linear relationship for risk of outcomes. This is 
clearest for LDL-C in relation to MI and death and SBP 
in relation to death and HF, for which levels lower than 
recommended by contemporary guidelines were asso-
ciated with lower risk for outcomes. Although we ac-
cept that CIs do cross 1.0 in some cases, this is likely 
the result of limited power (Figure 4). The combination 
of proportional hazard models and machine learning 
analyses offers a unique and complementary ability to 
study these associations. Machine learning takes into 
account complex higher-order interactions and offers 
more accuracy and robustness,8–10 whereas the Cox 
models provide the ability to assess strength of asso-
ciation without permitting age to drown out the effect 
of other risk factors. The combination of statistical ap-
proaches suggests that the robust predictability of re-
nal function and duration of diabetes mellitus may be 
integrated through (ie, in part explained by) age and 
other cardiometabolic risk factors, particularly by dys-
glycemia and SBP. The relative prognostic importance 
of HbA1c is lower in the machine learning models com-
pared with the Cox models, whereas albuminuria and 
SBP are prognostically more important in the machine 
learning models. This suggests that a significant inter-
action among age, HbA1c, SBP, and albuminuria modi-
fies the relative prognostic importance of these risk fac-
tors. Smoking demonstrated a low relative importance 
for all outcomes in our study, probably a result in part 
of the overall low prevalence of smoking.
Randomized trials have provided inconsistent evi-
dence with regard to glycemic control and its relation-
ship with macrovascular complications.11–14 The DCCT 
(Diabetes Control and Complications Trial) evaluated 
the effects of intensive glycemic control, and after 
years of follow-up in the EDIC study (Epidemiology of 
Diabetes Interventions and Complications), investiga-
tors observed a significant risk reduction for cardiovas-
cular disease.11–15 Our study shows that for death, each 
1-mmol/mol higher HbA1c was associated with an ≈2% 
higher relative risk or ≈23% higher relative risk per 1% 
higher HbA1c. The Cox model results also revealed that 
physical inactivity is an important predictor for stroke, 
whereas the machine learning models show the in-
creasing prognostic importance of SBP, with heteroge-
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Figure 5. Strength of association of predictors for the selected risk factors glycohemoglobin (HbA1c), systolic blood pressure (SBP), low-density lipo-
protein cholesterol (LDL-C), and estimated glomerular filtration rate (eGFR) in patients with type 1 diabetes mellitus. 
We constructed gradient boosting models to estimate the most important predictors for the selected risk factors HbA1c, SBP, LDL-C, and eGFR. The measure of 
strength of association in gradient boosting is denoted as relative influence. (A) HbA1c, (B) SBP, (C) LDL-C, and (D) eGFR.
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neity of the association by varying age and degree of 
hyperglycemia.16
Awareness of cardiovascular disease risk in patients 
with hypercholesterolemia and T1DM has increased 
over time, yet contemporary data indicate that control 
on the population level remains suboptimal.17,18 For the 
present analyses, LDL-C was a strong predictor for MI, 
stroke, and HF, demonstrating ≈35% to 50% higher 
relative risk for each 1-mmol/L increase. Thus, patients 
with T1DM who have not developed cardiovascular dis-
ease, specifically younger patients, might benefit from 
more aggressive primary cardiovascular risk prevention 
efforts and perhaps efforts initiated earlier in the course 
of disease.18–21 This is an important clinical point because 
currently statins are less commonly used in patients with 
T1DM who are <40 years of age,22 and some clinicians 
remain unconvinced of the merits of statins in the care 
of their patients with T1DM despite some evidence. Our 
observational data showed strong associations between 
LDL-C and long-term cardiovascular risk in patients with 
T1DM (in particular, MI, with risks being lower at even 
lower levels), which adds important support for target-
ing LDL-C in T1DM to prevent vascular disease.
Previous studies claim that kidney dysfunction, in 
the form of microalbuminuria, macroalbuminuria, or 
reduced eGFR, fully accounts for the excess cardiovas-
cular risk in T1DM.13,23 Our analyses imply that albu-
minuria is a strong risk factor for virtually all outcomes, 
associated with 2 to 4 times greater relative risk, with 
an overlap between various risk factors for albuminuria 
and cardiovascular disease, including hyperglycemia, 
hypertension, and hypercholesterolemia. Therefore, al-
buminuria is likely to represent an integrated estimate 
of several interrelated pathobiological mediators (ie, 
an integrated marker for the severity and duration of 
the perturbations of these risk factors). The present re-
sults suggest that intensive glycemic therapy may act 
through reducing microalbuminuria and macroalbu-
minuria and preserving eGFR, with findings from the 
DCCT directly supporting this notion.15
SBP, as expected, was a powerful predictor for car-
diovascular disease, particularly for stroke. The long-term 
observations from the DCCT showed that higher HbA1c 
was strongly associated with higher risk of hypertension, 
and intensive glycemic control reduced long-term risk of 
hypertension by 24%.24 Other studies show that roughly 
30% of patients with T1DM have hypertension and that 
hypertension is correlated with duration of diabetes 
mellitus, severity of hyperglycemia, and risk for devel-
opment and progression of diabetic kidney disease.25,26
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Figure 6. Gradient boosting for mortality and cardiovascular outcomes in patients with type 1 diabetes mellitus: partial dependence plots for the 
strongest predictors. 
These 2-way partial dependence plots show the dependence between either age or duration of diabetes mellitus and 1 of the 5 most important predictors, mar-
ginalizing over the values of all other features. These are generated with gradient-boosting models for mortality and cardiovascular outcomes in patients with type 
1 diabetes mellitus and enable us to visualize interactions among predictors. (A) All-cause mortality, (B) nonfatal/fatal acute myocardial infarction, (C) nonfatal/fatal 
stroke, and (D) hospitalization for heart failure. *The y axis denotes the probability of an event during a 10.4-year period and ranges between 0 and 1.
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Studies focused on determining optimal levels of 
cardiovascular risk factors for patients with T1DM are 
scarce, with clinical context and recommendations 
somewhat extrapolated from randomized trials in type 
2 diabetes mellitus. The present results show that lower 
SBP, HbA1c, and LDL-C levels are each associated with 
lower risk for cardiovascular outcomes and death, with 
a linear association for each with all outcomes assessed, 
except for mortality, for which HbA1c displayed a U-
shaped association. Observational assessment of opti-
mal levels is complicated because of reverse causality, 
residual confounding, and other factors limiting epide-
miological data. Nevertheless, associations with out-
comes were linear below levels presently recommended 
as guideline targets, and whether these targets should 
be more intensive in patients with T1DM should be as-
sessed in future trials.
Strengths and Limitations
Virtually all patients with T1DM in Sweden are included 
in this observational study, with information available 
on comorbidities, medications, and risk factors. How-
ever, a minority of registrants had complete data avail-
able on all 17 characteristics assessed, requiring the 
use of imputation for missing data. An epidemiological 
definition of T1DM was used that may lack phenotypic 
precision, although this definition has been validated 
as highly accurate previously. Although both conven-
tional and novel statistical approaches were used in our 
assessments of the strength of association of predic-
tors adding complementary information, the results are 
model-dependent and could change slightly with dif-
ferent model building. We relied on baseline character-
istics to model long-term outcomes, and it is likely that 
the results would be more accurate with time-updated 
information on risk factors during the period of obser-
vation. However, our approach mitigates to some de-
gree the risk of reverse causation biasing the results. 
Finally, although numerous risk factors were accounted 
for in the adjusted models, it is not possible to com-
pletely overcome the limitation of residual confound-
ing. A lower event number in those with risk factor 
levels at or below current target values means that CIs 
were inevitably wider. Therefore, some caution in inter-
pretation is needed, although it is notable that patterns 
for associations for the 4 outcomes we examined in de-
tail were broadly consistent.
CONCLUSIONS
Using data from a nationwide population-based cohort 
and state-of-the-art statistical methods, we found that 
the strongest predictors for cardiovascular outcomes and 
death are HbA1c, albuminuria, duration of diabetes mel-
litus, LDL-C, and SBP during an average of 10 years of 
follow-up in individuals with T1DM. HbA1c is a strong 
predictor for all outcomes, and its association is likely in-
tegrated with albuminuria and duration of diabetes mel-
litus, whereas LDL-C and SBP display independent predict-
ability. LDL-C appears to be a more important prognostic 
factor than previously appreciated. Therefore, we believe 
that further research is warranted to delineate the poten-
tial benefit of more aggressive LDL-C lowering in patients 
with T1DM than currently practiced. The results also sug-
gest a linear association for cardiovascular risk factors 
extending below thresholds used as contemporary treat-
ment targets, and whether targeting lower levels may be 
clinically beneficial should be the focus of future trials.
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